home / stock / mrus / mrus articles
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company dev...
– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 20...
Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potent...
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagriss...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today a...
2024-06-27 10:45:04 ET Aurora Innovation Inc (AUR) AUR is trading UP for the last 5 days, and it at trading at $2.79 with volume of 1,962,658 and a one day change of $0.15 (5.67%). Aurora Innovation Inc has a 52-week low of 1.30 and a 52-week high of $4.81. The business's 50-day mov...
2024-06-17 09:00:05 ET Bradley Canino from Stifel Nicolaus issued a price target of $99.00 for MRUS on 2024-06-17 07:26:00. The adjusted price target was set to $99.00. At the time of the announcement, MRUS was trading at $56.55. The overall price target consensus is at ...